PMC:7299399 / 15527-16139 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T63","span":{"begin":32,"end":38},"obj":"Disease"},{"id":"T64","span":{"begin":179,"end":189},"obj":"Disease"},{"id":"T65","span":{"begin":316,"end":324},"obj":"Disease"},{"id":"T66","span":{"begin":423,"end":431},"obj":"Disease"}],"attributes":[{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T169","span":{"begin":4,"end":7},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T170","span":{"begin":338,"end":340},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T171","span":{"begin":405,"end":406},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T172","span":{"begin":555,"end":560},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":32,"end":38},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}

{"project":"LitCovid-sentences","denotations":[{"id":"T72","span":{"begin":203,"end":262},"obj":"Sentence"},{"id":"T73","span":{"begin":263,"end":432},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}

{"project":"LitCovid-PubTator","denotations":[{"id":"246","span":{"begin":32,"end":38},"obj":"Disease"},{"id":"247","span":{"begin":179,"end":198},"obj":"Disease"},{"id":"252","span":{"begin":316,"end":326},"obj":"Species"},{"id":"253","span":{"begin":555,"end":560},"obj":"Species"},{"id":"254","span":{"begin":423,"end":431},"obj":"Disease"}],"attributes":[{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"MESH:D009369"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"MESH:D003141"},{"id":"A252","pred":"tao:has_database_id","subj":"252","obj":"Tax:2697049"},{"id":"A253","pred":"tao:has_database_id","subj":"253","obj":"Tax:9606"},{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}

{"project":"2_test","denotations":[{"id":"32519842-30599229-158484","span":{"begin":199,"end":201},"obj":"30599229"}],"text":"ics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.58\n\nNanomaterial-Based Vaccine Development and Immunomodulation\nFollowing the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel c"}